Critical Insights From Surgery Partners Analyst Ratings: What You Need To Know
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Surgery Partners (NASDAQ:SGRY) in the latest quarter, with 2 bullish and 2 somewhat bullish ratings. The average 12-month price target has decreased to $40.5 from $46.00. Key analysts have adjusted their ratings and price targets, reflecting evolving market conditions and company performance.
June 28, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Surgery Partners (NASDAQ:SGRY) received mixed analyst ratings with a decrease in the average 12-month price target to $40.5. Key analysts have adjusted their ratings and price targets, reflecting evolving market conditions and company performance.
The mixed ratings and decreased average price target indicate uncertainty among analysts about the future performance of Surgery Partners. While some analysts remain bullish, the overall sentiment has become more cautious, which could lead to neutral short-term price movements.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100